Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements
The immune checkpoint inhibitors (ICTs) emergence has opened up new perspectives in cancer immunotherapy. Nevertheless, serious, including life-threatening conditions caused by ICT cardiotoxic effects pose a number of obstacles to clinical specialists. The lack of knowledge about pathophysiology of...
Saved in:
| Main Authors: | L. D. Khidirova, A. E. Latsvieva, A. V. Vederin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2024-06-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/3022 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy
by: Aya F. Ozaki, et al.
Published: (2025-03-01) -
Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors
by: Michael Sayer, et al.
Published: (2025-04-01) -
Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
by: Harun Muğlu, et al.
Published: (2025-02-01) -
Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
by: Joshua Longinow, et al.
Published: (2023-02-01) -
Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database
by: Guojing Yao, et al.
Published: (2025-08-01)